Drugs / MIL93
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04671875 | Apr 2021 → Aug 2025 | cancer | Beijing Mabworks Biotech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIL93 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04671875 ↗ |
| Modality | Monoclonal antibody | “MIL93 is a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody.” NCT04671875 ↗ |
| Route | Intravenous | “Each patient will receive an intravenous infusion of MIL93 every 3 or 2 week on Day 1.” NCT04671875 ↗ |
| Target | CLDN18 | “MIL93 is a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody.” NCT04671875 ↗ |